ClinicalTrials.gg
RecruitingNCT05303064Updated Nov 20, 2026

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

A Phase 3 interventional study of OLZ/SAM and Olanzapine in Schizophrenia and Bipolar I Disorder, sponsored by Alkermes, Inc.. Recruiting at 47 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.
Updated Nov 20, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Schizophrenia by Alkermes, Inc. — 2 open to participants now, 2 under way, 2 of them phase 3. Schizophrenia · Alkermes, Inc..

Planned enrollment
13th of 19
220 · median 281
Started
2022
the only one that year
Phase 3
12 of 21
2 open now
Registered
20th of 21
by date

Among the 21 studies in Schizophrenia by Alkermes, Inc., this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 12 in phase 3, and was the 20th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 21 studies in Schizophrenia by Alkermes, Inc. are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Schizophrenia by Alkermes, Inc., or all of them as a file.
02

Study summary

To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

03

Conditions studied

  • Schizophrenia
  • Bipolar I Disorder

Browse trials for

Keywords

  • LYBALVI
  • Schizophrenia
  • Bipolar I Disorder
  • Pediatric
  • Olanzapine
  • Samidorphan
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 13 to 17 years with schizophrenia or aged 10 to 17 years with bipolar I disorder, diagnosed according to , 5th Edition (DSM-5) criteria
  • Subject is an outpatient or will be able to be treated on an outpatient basis (per Investigator judgement) by study Week 2
  • Subject has reliable family/legal guardian support available for outpatient management
  • Subject is either currently treated with olanzapine, or if treated with another antipsychotic, the subject has had an inadequate response (eg, unsatisfactory clinical response, AEs, or nonadherence to current medication) based on Investigator judgment
  • Subject must not be a danger to self or others (per Investigator judgement)

Exclusion criteria

Exclusion Criteria:

  • Subject presents with a major depressive episode(bipolar I disorder) or other neuropsychiatric diagnosis (according to criteria) including schizoaffective disorder, current major depressive disorder that is untreated and/or unstable, or any other psychiatric condition that could interfere with participation in the study
  • Subject has a history of seizure disorder (exception: history of febrile seizures), severe head trauma with loss of consciousness within the 12 months prior to Screening, or other neurological condition within the 12 months prior to Screening
  • Subject poses a current suicide risk as assessed by the Investigator or as confirmed by the baseline Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Subject has received olanzapine for >= 14 days during the month prior to screening, or has a history of poor or inadequate response to treatment with olanzapine
  • Subject has taken opioid agonists within 14 days prior to Screening, or within 30 days prior to Screening (for long-acting opioid agonists)
  • Subject anticipates needing to take opioid medication during the study period (eg, planned surgery, including oral surgery)
  • Subject has taken opioid antagonists including naltrexone (any formulation) or naloxone within 60 days prior to Screening
  • Subject has used a long-acting injectable antipsychotic medication within 3 injection cycles prior to Screening
  • Subject has a percentile >98th or \<5th
  • Subject has a diagnosis of diabetes mellitus or presents with prediabetes lab results at Screening ( [HbA1c] >= 6%)
  • Subject has started a smoking cessation program within the 6 months prior to Screening or has joined a weight management program or has had significant changes in diet or exercise regimen within 6 weeks prior to Screening
  • Subject has participated in a clinical study of an product within the last 30 days prior to Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Group 1 OLZ/SAM

    Fixed dose combination of olanzapine and samidorphan

    Drug: OLZ/SAM

  • Active comparator
    Group 2 Olanzapine

    Fixed dose of olanzapine

    Drug: Olanzapine

Interventions

  • DrugOLZ/SAM

    Drug page: S-AdenosylmethionineStudies of S-AdenosylmethionineS-Adenosylmethionine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.

    Also known as: ALKS 3831, LYBALVI

  • The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day

06

What researchers measure

Primary outcomes

  1. Change from baseline in body mass index (BMI) Zscore at week 12

    To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of subjects with >=0.5 increase in BMI Z-score at Week 12

    To compare subjects with clinical significant BMI Z-score increase with OLZ/SAM vs olanzapine

    Time frame: 12 weeks

  2. Time to all-cause discontinuation of study drug over 52 weeks

    To compare time to all-cause discontinuation of study drug with OLZ/SAM vs olanzapine

    Time frame: Up to 52 weeks

  3. Change from baseline in waist circumference

    To compare the change from baseline in waist circumference with OLZ/SAM vs olanzapine

    Time frame: 12 weeks

  4. Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score for patients with schizophrenia by visit

    To compare the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score with OLZ/SAM vs olanzapine for patients with schizophrenia

    Time frame: 12 weeks

  5. Change from baseline in Young Mania Rating Scale (YMRS) in patients with Bipolar I disorder

    To compare the change from baseline in YMRS with OLZ/SAM vs olanzapine for patients with bipolar I disorder

    Time frame: 12 weeks

  6. Change from baseline in Children's Depression Rating Scale-Revised (CDRS-R) for patients with bipolar I disorder by visit

    To compare the change from baseline in CDRS-R with OLZ/SAM vs olanzapine for patients with bipolar I disorder

    Time frame: 12 weeks

  7. Incidence of Adverse Events

    Time frame: Up to 52 weeks

07

Study locations

32 of 47 sites recruiting
  • Alkermes Investigator Site
    Dothan, Alabama 36303, United States
    Recruiting
  • Alkermes Investigator Site
    Little Rock, Arkansas 72204, United States
    Recruiting
  • Alkermes Investigator Site
    Encino, California 91316, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Stanford, California 94305, United States
    Recruiting
  • Alkermes Investigator Site
    Upland, California 91786, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Colorado Springs, Colorado 80910, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Denver, Colorado 80202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Hartford, Connecticut 06106, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Alkermes Investigator Site
    Miami, Florida 33155, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Alkermes Investigator Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Alkermes Investigator Site
    Chicago, Illinois 60611, United States
    Recruiting
  • Alkermes Investigator Site
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Saint Charles, Missouri 63304, United States
    Recruiting
  • Alkermes Investigator Site
    Lincoln, Nebraska 68526, United States
    Recruiting
  • Alkermes Investigator Site
    Omaha, Nebraska 68198, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Paramus, New Jersey 07652, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    New York, New York 10016, United States
    Recruiting
  • Alkermes Investigational Site
    Kinston, North Carolina 28504, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Alkermes Investigator Site
    West Chester, Ohio 45069, United States
    Recruiting
  • Alkermes Investigator Site
    DeSoto, Texas 75115, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Fort Worth, Texas 76104, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Alkermes Investigational Site
    Richmond, Virginia 23220, United States
    Recruiting
  • Alkermes Investigator Site
    Everett, Washington 98201, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    La Plata, Buenos Aires 1900, Argentina
    Recruiting
  • Alkermes Investigator Site
    La Plata, Buenos Aires C1199ABB, Argentina
    Recruiting
  • Alkermes Investigator Site
    Buenos Aires, C1133AAH, Argentina
    Recruiting
  • Alkermes Investigator Site
    Córdoba, X5003DCE, Argentina
    Recruiting
  • Alkermes Investigator Site
    Mendoza, 5500, Argentina
    Recruiting
  • Alkermes Investigator Site
    Fortaleza, Ceará 60430-140, Brazil
    Recruiting
  • Alkermes Investigator Site
    Curitiba, Paraná 80240-280, Brazil
    Recruiting
  • Alkermes Investigator Site
    Goiânia, 74093-040, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Rio de Janeiro, 22270-060, Brazil
    Recruiting
  • Alkermes Investigator Site
    São Paulo, 01228-000, Brazil
    Recruiting
  • Alkermes Investigator Site
    São Paulo, 05403-010, Brazil
    Recruiting
  • Alkermes Investigator Site
    Barranquilla, 110121, Colombia
    Recruiting
  • Alkermes Investigator Site
    Bello, 51053, Colombia
    Recruiting
  • Alkermes Investigator Site
    Bogotá, 111166, Colombia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Alkermes Investigator Site
    Bogotá, 80020, Colombia
    Recruiting
  • Alkermes Investigator Site
    Pereira, 660003, Colombia
    Recruiting
  • Alkermes Investigator Site
    Culiacán, 80230, Mexico
    Recruiting
  • Alkermes Investigator Site
    Estado de México, C.P. 07000, Mexico
    Recruiting
  • Alkermes Investigator Site
    León, 37000, Mexico
    Recruiting
  • Alkermes Investigator Site
    Monterrey, 64620, Mexico
    Recruiting
  • Alkermes Investigator Site
    Monterrey, 64710, Mexico
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2027, 66 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 66 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2022
First posted
Mar 31, 2022
StartActual
Jun 30, 2022
Primary completionEst.
Dec 2027was Sep 2026
CompletionEst.
Dec 2027was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now active, not recruiting)
Show 3 sites
  • Alkermes Investigator Site · Indianapolis, United StatesRecruiting→Active, not recruiting
  • Alkermes Investigator Site · Everett, United StatesRecruiting→Active, not recruiting
  • Alkermes Investigator Site · Goiânia, BrazilRecruiting→Active, not recruiting
Nov 20, 2026
Primary completion
Sep 2026→Dec 2027
Nov 20, 2026
Study completion
Sep 2026→Dec 2027
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    3 sites changed recruiting status (3 now active, not recruiting)
    Show 3 sites
    • Alkermes Investigator Site · Indianapolis, United StatesRecruiting→Active, not recruiting
    • Alkermes Investigator Site · Everett, United StatesRecruiting→Active, not recruiting
    • Alkermes Investigator Site · Goiânia, BrazilRecruiting→Active, not recruiting
    Primary completion Sep 2026→Dec 2027
    Study completion Sep 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05303064
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Jun 30, 2022
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Global Clinical Services
Contact
clinicaltrials@alkermes.com
888-235-8008 (US Only)
Global Clinical Services
Contact
clinicaltrials@alkermes.com
1-571-599-2702 (Global)
David McDonnell, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: S-Adenosylmethionine

Start the discussion